Viking Therapeutics, Inc. VKTX
Viking Therapeutics, Inc. (Nasdaq: VKTX) is a cardio-renal-metabolic drug developer. Its lead program, VK2735 (subcutaneous formulation), is in Phase 3 for obesity. Its next catalyst on record is VK2735 subcutaneous: VANQUISH-1 and VANQUISH-2 data readouts (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VK2735 subcutaneous — VANQUISH-1 and VANQUISH-2 data readouts (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VK2735 (subcutaneous) | obesity | protein/peptide | Phase 3 |
| VK2735 (oral formulation) | obesity | protein/peptide | Phase 3 |
| VK2809 (TRβ agonist) | NASH/MASH | small molecule | Phase 2 |
| VK5211 (SARM) | hip fracture recovery / sarcopenia | small molecule | Phase 2 |
| VK3019 (amylin agonist) | obesity | protein/peptide | Phase 1 |
| VK0214 (TRβ agonist) | X-linked adrenoleukodystrophy (X-ALD) | small molecule | Phase 1 |
Recent results and decisions
- Oct 28, 2026positive Positive top-line results from Part 1 of VK2735 maintenance dosing study showed weight loss retention of 82-97% with every-other-week or monthly dosing compared to 61% for placebo.
Among subjects dosed every-other-week, mean weight loss retained at Week 33 ranged from 83% to 97%, compared with 61% among subjects transitioned from 17.5 mg weekly to placebo, with p-values less than 0.01 for each cohort vs. placebo.
Filing - Oct 28, 2026started Part 2 of VK2735 maintenance dosing study initiated to evaluate oral and additional subcutaneous regimens.
Following the successful initial readout, we announced another milestone with the initiation of Part 2 of the maintenance study.
Filing - started SUNRISE Phase 3 program for oral VK2735 initiated, including SUNRISE-1 in adults with obesity and SUNRISE-2 in obese/overweight adults with type 2 diabetes.
Earlier this month, the company announced the initiation of the SUNRISE Phase 3 registration program evaluating oral VK2735.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.